The partners of the PragmaTIL consortium have gathered in Barcelona to hold its first annual meeting. Asphalion’s experts Montse Domingo and Nuria García Pazos attended the meeting.
After this first year of work, the submission of CTA to the CTIS portal for Spain, Denmark and the Netherlands has been completed. Asphalion, as the regulatory partner, has been in charge of supervising and coordinating the regulatory path, focusing on the submission of the clinical trial and the safety management plan.
During this meeting, the partners have been able to review all the work carried out to date, as well as focusing on the next steps, which include aiming for the start of the clinical trials on Q4, 2024.
The PragmaTIL trial aims to optimize treatment of cancer patients with Tumour-Infiltrating Lymphocytes Adoptive Cell Therapy (TIL-ACT) and substantially expand and improve the clinical implementation of this treatment modality in academic hospitals. To this end, treatment related toxicities, associated to high-dose interleukin 2 (HD-IL-2) required for expansion and activation of TILs will be reduced while maintaining efficacy.
To learn more about the project, please visit: PRAGMATIL PROJECT WEBSITE
For further information, you can contact us at: [email protected]
